HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Rhea-AI Summary

HOOKIPA Pharma (NASDAQ: HOOK) is set to present preclinical data for its HB-700 program, targeting KRAS mutated cancers, at the 6th Annual RAS-Targeted Drug Development Summit in Boston from September 24-26, 2024. The company's Chief Research & Development Officer, Mark Winderlich, PhD, highlighted that HB-700 is uniquely positioned to target multiple prevalent KRAS mutations in pancreatic, colorectal, and lung cancers within a single therapy.

Key points:

• HB-700 is designed as a potential multi-KRAS therapy
• Preclinical data shows safety, induction of target-specific CD8+ T-cells, and target cell killing
• FDA granted IND clearance in Q2 2024, making HB-700 Phase 1 ready

The virtual oral presentation, titled 'Development of an Arenavirus-Based Immunotherapy for Treatment of KRAS Mutant Cancer,' is scheduled for September 25, 12:45 to 1:15 PM ET, during the Drug Discovery & Preclinical Development session.

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024

NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6^th Annual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September 24-26, 2024.

“HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy,” said Mark Winderlich, PhD, Chief Research & Development Officer. “HOOKIPA’s approach could enable HB-700 to be a widely used, multi-KRAS therapy. The preclinical dataset has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models. With IND clearance, received from the FDA in Q2 2024, HB-700 is a Phase 1 ready asset.”

Presentation Details:

• Oral Presentation (Virtual): Development of an Arenavirus-Based Immunotherapy for Treatment of KRAS Mutant Cancer
• Session: Drug Discovery & Preclinical Development
• Presentation Date/Time: Wednesday, September 25, 12:45 to 1:15 PM ET

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing next generation immunotherapeutics based on its proprietary arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. HOOKIPA’s pipeline includes biological therapies for oncology, targeting human papillomavirus 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, HOOKIPA has partnered with Gilead to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Find out more about HOOKIPA online at www.hookipapharma.com.

Forward Looking Statements
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “anticipates”, “believes”, “expects”, “plans”, “potential”, “will”, “would” or similar expressions and the negative of those terms. Forward-looking statements in this press release include HOOKIPA’s statements regarding the potential of its product candidates to alter the course of disease in the patients it seeks to treat. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, plans and timelines for the preclinical and clinical development of its product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs, the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including those for eseba-vec, HB-700, HB-400 and HB-500, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, and HOOKIPA’s ability to continue as a going concern and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see HOOKIPA’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at https://sec.gov and HOOKIPA’s website at www.hookipapharma.com. All information in this press release is as of the date of the release, and HOOKIPA undertakes no duty to update this information unless required by law.

Availability of Other Information About HOOKIPA
Investors and others should note that we announce material financial information to our investors using our investor relations website, www.ir.hookipapharma.com, SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website.

For further information, please contact:

Investors
Chuck Padala
Chuck@LifeSciAdvisors.com

FAQ

What is HOOKIPA Pharma presenting at the RAS-Targeted Drug Development Summit in September 2024?

HOOKIPA Pharma (HOOK) is presenting preclinical data for its HB-700 program, which targets KRAS mutated cancers, at the 6th Annual RAS-Targeted Drug Development Summit from September 24-26, 2024 in Boston.

What types of cancer does HOOKIPA's HB-700 program target?

HOOKIPA's HB-700 program targets KRAS mutated cancers, which are most frequently found in pancreatic, colorectal, and lung cancers.

When did HOOKIPA receive FDA clearance for HB-700?

HOOKIPA received FDA IND clearance for HB-700 in Q2 2024, making it a Phase 1 ready asset.

What makes HOOKIPA's HB-700 program unique in targeting KRAS mutations?

Unlike programs focused on a single mutation, HOOKIPA's HB-700 is uniquely suited to target the most prevalent KRAS mutations in pancreatic, colorectal, and lung cancers within a single therapy.

What results has HOOKIPA's HB-700 shown in preclinical studies?

The preclinical dataset for HB-700 has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models.